When stairs take more out of you
What each comparison can answer about your health
A flight of stairs may concern you more than a lighter weight. These substances were tested in different illnesses; compare who took part before expecting the same help for yourself.
The short answer: different groups answer different questions
Stairs and chores can remain hard work even after weight loss. Judging a benefit means checking the people treated and the change the study counted.
Large groups with weight or blood-sugar problems received semaglutide or tirzepatide. Tesamorelin mainly concerns unusual fat gathering around belly organs in HIV patients.
MOTS-c treatment experiments used animals, cells, or mixtures of cell parts. These sources don't contain a human trial testing treatment with MOTS-c.
In a direct trial, tirzepatide produced a bigger average loss of weight than semaglutide [1]. Tesamorelin groups had lower liver fat, along with less fat beside belly organs [12][14][16].
Mice treated with MOTS-c moved better in tests [20]. The differences between these findings keep us from treating them as proof of restored youth.
Studies didn't check tiredness and daily tasks as consistently as weight or blood sugar. I'd bring your main difficulty to the doctor and ask which finding addresses that problem.
What was tested for each substance
| Peptide | People or animals studied | Action studied | What changed and what remains unknown |
|---|---|---|---|
| Semaglutide | Adults with excess weight; other trials involved diabetes or heart or kidney illness | Acts like GLP-1, a gut hormone involved in appetite as well as sugar levels in blood | Weight fell; certain groups had a decrease in serious heart or kidney illness [2][3][4]. Your energy needs a separate test. |
| Tirzepatide | Adults with excess weight; some groups had type 2 diabetes | imitates the meal-related hormones GIP and GLP-1 | Weight decreased alongside sugar levels; direct trials showed a larger weight loss than semaglutide [1][10][11]. Better energy wasn't established by personal accounts. |
| Tesamorelin | HIV patients with unusual deep belly fat | prompts release of the body's own growth hormone | Fat near belly organs decreased [12][14][16]. You can't assume more strength or energy from that change. |
| MOTS-c | Mice, cells, and kidney patients needing dialysis, the cleaning of blood by a machine | Affects muscle sugar use and cells facing an energy shortage | Mouse movement improved; higher natural human blood readings went with a greater combined chance of death or serious illness of the heart [17][18][20][21]. Nobody tested treatment in people. |
What appetite changes cannot say about other fat treatments
Both semaglutide and tirzepatide imitate GLP-1, a hormone your gut releases. More insulin is released in response to higher blood sugar, and the stomach holds onto a meal longer.
Tirzepatide also imitates GIP, another gut hormone involved in meals. The average loss of weight was greater with tirzepatide when researchers compared the drugs over the same period [1].
You can't infer the same advantage for energy or the effort of chores. Those benefits need questions and tests aimed at daily tasks.
Growth hormones rose with tesamorelin, and HIV patients lost fat around belly organs [12][14][16]. Their illness limits how your doctor can apply those results to you.
In lab experiments, MOTS-c affected sugar use and cells responding to too little energy [17][19][21]. An interest in weight doesn't give all four substances the same treatment use.
What human trials establish more firmly than mouse tests
Different semaglutide trials tested different health problems, limiting what each can tell you. Adults lost weight in the trial named STEP 1 [4].
A heart trial found fewer serious problems in overweight people whose hearts were already diseased but who didn't have diabetes [3]. A kidney trial found fewer people having kidney failure, major kidney decline, or related deaths counted together [2].
Large studies have tested tirzepatide in people, sometimes directly against semaglutide [1][10][11]. Both medicines caused digestive trouble; the review found more cases with tirzepatide after adding gallbladder illnesses to bile-tube illnesses [9].
Tesamorelin trials mainly tested HIV patients with unusual fat buildup, instead of the usual causes of gaining weight. Liver fat decreased alongside fat beside organs farther inside the belly; weight excluding fat rose [12][14][16].
That weight includes organs and water, so the rise doesn't establish muscle gain alone. Your visit needs time to match your illness to the one tested.
The MOTS-c human study watched blood readings and later illness without giving treatment [18]. The evidence for treatment therefore isn't equally strong across these substances.
What researchers counted instead of daily energy
Semaglutide studies counted weight changes and checked appetite, side effects, and illness of kidneys or the heart [2][3][4][5][6]. Those checks don't cover every benefit you might hope to get.
Tirzepatide studies checked weight loss and sugar levels, sometimes comparing treatment against semaglutide [1][9][10][11]. A review also counted pancreas problems and illness of gallbladders or tubes carrying bile.
Tesamorelin studies checked growth hormones, liver fat, belly fat, and fat gathering again once treatment ended [12][14][15][16]. MOTS-c tests checked mouse muscles, cell changes, and people's natural blood readings [17][18][20][21].
These studies weren't one contest to identify the best help for your tiredness. Ask which study checked your daily difficulty rather than a different health concern.
What could establish that people had more energy
An energy study needs clear questions chosen before researchers see the results. Your concern calls for tests of tasks and direct questions about tiredness.
A study could check people's sleep, walks, and chores before treatment and afterward, while also counting early problems, lasting effects, and people who quit treatment or stopped answering questions. Otherwise, an apparent improvement could hide people who had a harder time.
A change too small to feel won't necessarily help you through the afternoon. The useful benefit is doing more or feeling less tired in daily life.
Energy wasn't checked alike across all four substances in these sources. People's accounts suggest questions to test, but trials haven't checked the causes of those accounts.
Broad human trials tested semaglutide and tirzepatide; tesamorelin has a narrower approved use. MOTS-c treatment findings remain in animals and labs, leaving your energy question open.